Idiotype-derived peptide–Major Histocompatibility Complex (Id-pMHC)

Idiotype-derived peptide–Major Histocompatibility Complex (Id-pMHC) complexes are specialized molecular targets formed when fragments of a unique B-cell or T-cell receptor variable region (the idiotype) are processed and presented on the cell surface by MHC molecules (Bogen et al., 1993, Eur J Immunol). In B-cell malignancies such as multiple myeloma and follicular lymphoma, the idiotype serves as a truly tumor-specific neoantigen because it is unique to the clonal population of malignant cells and absent from healthy tissues (Lynch et al., 1985, J Exp Med). These complexes are recognized by the T-cell receptor (TCR) of CD4+ or CD8+ T-cells, which can trigger a targeted adaptive immune response against the tumor. Therapeutic strategies have historically focused on idiotype vaccines, such as BiovaxID, which aim to induce endogenous T-cell and B-cell responses (Levy et al., 2014, J Clin Oncol). Recent advancements have shifted toward TCR-engineered T-cell therapies that directly target these complexes with high affinity to overcome the low natural frequency of idiotype-specific T-cells (Hunder et al., 2008, N Engl J Med). Because the idiotype is patient-specific, these therapies represent a form of highly personalized medicine. However, the clinical efficacy of targeting Id-pMHC has been limited by the inherent low immunogenicity of these peptides and the ability of tumors to escape immune pressure by downregulating MHC expression or the idiotype itself (Weng et al., 2004, Blood).

Other names

Idiotype-MHC complexId-peptide-MHCB-cell receptor idiotype-derived peptide-MHC complexT-cell receptor idiotype-derived peptide-MHC complexMyeloma idiotype-MHC complex

Stimulation of idiotype-specific T-cell mediated cytotoxicity or helper responses against malignant B-cells presenting idiotype fragments on MHC molecules.